TL;DR
The bronchial cousin of Epitalon. Zero human RCTs in English-indexed journals.
What is it? A synthetic tetrapeptide (Ala-Glu-Asp-Leu, AEDL) from Khavinson's St. Petersburg institute. Shares the Ala-Glu-Asp core with Epitalon (AEDG), Cortagen (AEDP), and Cardiogen (AEDR). Successor to the older polypeptide complex Broncholin.
What does it do? Khavinson's epigenetic-bioregulator model proposes AEDL binds DNA at bronchial-epithelial-gene promoters, modulating mucociliary function, tight-junction proteins, and local antioxidant defenses. Monaselidze (2011) documented DNA thermostability effects.
Does the evidence hold up? Preclinical only. Cell-culture and animal work shows bronchial cell differentiation and mucosal repair. No randomized controlled human trials of synthetic AEDL are published in English-indexed peer-reviewed journals.
Who uses it? Longevity circles running the Khavinson oral-capsule course, short cycles 2–3 times a year. Not a bronchodilator, not an asthma or COPD drug.
Bottom line? Still a lab curiosity. No human RCT has tested it in English.
What It Is
Bronchogen is a synthetic short peptide developed within the Khavinson peptide-bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology. The molecule is a tetrapeptide with the sequence Ala-Glu-Asp-Leu (AEDL) and an approximate molecular weight of 446 daltons. Structurally it is a close relative of several other Khavinson tissue-specific short peptides — it shares the N-terminal "Ala-Glu-Asp" acidic core with Epithalon (AEDG, pineal), Cortagen (AEDP, cortex), Cardiogen (AEDR, heart), and the cartilage peptide Cartalax, with a different C-terminal residue proposed to confer tissue specificity.
Bronchogen is the short-peptide successor to Broncholin, an earlier polypeptide complex extracted from calf bronchial tissue that was used in Soviet/Russian pulmonology. The Khavinson program's central claim is that the bioregulatory activity of tissue extracts can be distilled into defined short peptides (2–4 amino acids) recovered from hydrolysis of those extracts. Bronchogen (AEDL) is the candidate short peptide identified as the putative active fragment from the bronchial extract. Unlike Broncholin, Bronchogen is a chemically defined synthetic peptide, solid-phase-synthesized and purified to pharmaceutical grade.
Commercially, Bronchogen is distributed in two formats: as an oral capsule (typically 200 μg or similar microdose, formulated within the Khavinson "Revilab" / NPCRiZ bioregulator product line) and as a lyophilized research peptide (20 mg vials are typical) sold by research-chemical vendors for subcutaneous or intramuscular administration. The oral-capsule presentation is sold as a dietary supplement (BAD — "biologically active additive") in Russia; the injectable lyophilized powder is research-only internationally.
In the Western optimization community, Bronchogen is used primarily by individuals seeking respiratory-tissue support in the context of a broader Khavinson bioregulator stack. It is not a bronchodilator, inhaled corticosteroid, leukotriene modifier, or biologic — and has no place in the evidence-based management of asthma, COPD, or any respiratory disease. Mainstream Western pulmonology has no awareness of, or use for, the compound.
Mechanism of Action
The Khavinson group proposes that short bioregulator peptides act as sequence-specific DNA-binding molecules — short enough to enter cells and nuclei without dedicated transport, and chemically structured to dock in the major/minor groove of DNA at promoter regions of tissue-specific genes. Bronchogen's mechanism is described within this epigenetic-bioregulator framework. Importantly, this is a mechanism proposed by a single research group; independent structural validation is limited.
- Direct DNA interaction (proposed) — Fedoreyeva and colleagues (Fedoreyeva 2011, PMID 22117548) demonstrated that fluorescently labeled short Khavinson peptides penetrate the nucleus of HeLa cells. Monaselidze et al. (2011, Bulletin of Experimental Biology and Medicine 150:375-377) reported that AEDL alters the thermostability profile of DNA — interpreted as evidence of direct peptide-DNA interaction at specific sequences. The exact binding footprint and thermodynamic affinity are not well characterized.
- Bronchial epithelial differentiation — Khavinson, Linkova and colleagues (Bull Exp Biol Med 2012, 153(1):148-151) described tissue-specific stimulation of cell differentiation by short peptides in aged cell cultures; AEDL is reported to promote differentiation markers in bronchial epithelial cell models.
- Mucociliary machinery (proposed) — AEDL exposure is reported to modulate expression of mucin genes (MUC5AC), cilia-associated structural proteins, and tight-junction components (claudins, occludin, ZO-1) in bronchial epithelial models. The magnitude of effect described in the source literature is modest and model-dependent.
- Antioxidant / anti-apoptotic effects — Preclinical studies describe reduced oxidative-stress markers and reduced apoptosis in bronchial epithelial cells exposed to AEDL under oxidant challenge.
- Immune / cytokine modulation — Gumen, Kozinets, Shanin, Malinin, Rybakina (2006, Bull Exp Biol Med 142(3):360-362, PMID 17266159) described lymphocyte-activating-factor production by mouse macrophages under the influence of short Khavinson peptides, including AEDL — evidence of broader immunomodulation beyond the bronchial-epithelium compartment.
- Terminal-residue specificity hypothesis — The Khavinson model holds that the C-terminal residue (leucine in AEDL) drives tissue specificity. Replacing leucine with glycine (AEDG → Epithalon, pineal), proline (AEDP → Cortagen, cortex), arginine (AEDR → Cardiogen, heart), or lysine reportedly shifts the tissue affinity. Structural validation of this specificity claim is limited to the originating group's work.
- Systemic-epigenetic framing (Khavinson 2021 review) — Khavinson, Popovich, Linkova, Mironova, Ilina (Molecules 2021, 26(22):7053, PMID 34834147) published a systematic review of peptide regulation of gene expression, framing short-peptide bioregulators as epigenetic modulators acting on target genes' promoter methylation, histone status, and chromatin accessibility.
Limitation: the proposed mechanism remains primarily a hypothesis generated and refined by one research program. Structural biology validation (crystal structures, NMR binding footprints, independent ChIP-seq replication) at the level of what is available for well-characterized sequence-specific DNA binders is not available for Bronchogen.
What the Research Shows
The published Bronchogen literature is concentrated in a narrow set of Russian-language and English-language Springer-indexed journals, authored largely by the Khavinson group or close collaborators. Evidence is preclinical — cell culture and animal models — with no randomized, placebo-controlled human trials of the synthetic tetrapeptide indexed in PubMed or other Western databases.
- DNA thermostability (Monaselidze 2011) — Reported altered melting profile of DNA incubated with AEDL, interpreted as sequence-specific interaction. Biophysical foundation for the direct-DNA-binding hypothesis.
- Nuclear penetration (Fedoreyeva 2011, PMID 22117548) — Fluorescein-labeled short Khavinson peptides were tracked into the nuclei of HeLa cells, demonstrating that AEDL and sibling peptides can reach the nuclear compartment at accessible concentrations.
- Tissue-specific differentiation (Khavinson/Linkova 2012, Bull Exp Biol Med 153:148-151) — Described differentiation-promoting effects of short peptides in aged tissue cultures; AEDL-class peptides promoted bronchial-specific differentiation markers.
- Cytokine modulation (Gumen 2006, PMID 17266159) — Short Khavinson peptides, including AEDL, influenced lymphocyte-activating-factor production by aged murine macrophages — an immunologic axis independent of strict "bronchial" effects.
- Peptide gene-regulation review (Khavinson 2021, PMID 34834147) — Systematic review of Khavinson-program peptide bioregulator literature, including AEDL, within the broader epigenetic-modulator framework. Comprehensive reference for the program's claims and evidence base.
- Broncholin parent-extract era — Earlier Russian pulmonology literature on the polypeptide tissue extract (not the synthetic tetrapeptide) described observational improvements in chronic bronchitis, post-infectious respiratory recovery, and age-related respiratory function. Those reports do not directly validate AEDL and are methodologically limited by pre-modern trial standards.
- Plant-biology corollary (Kononenko & Fedoreyeva) — Notably, AEDL has been shown to stimulate root development in Nicotiana tabacum in combination with glutathione — a striking cross-kingdom observation that some authors interpret as supporting deep, evolutionarily conserved sequence-recognition activity of the peptide.
- Clinical bronchial disease — no evidence — No published randomized, placebo-controlled trials of synthetic AEDL (Bronchogen) for asthma, COPD, bronchiectasis, post-infectious recovery, or respiratory long-COVID exist in English-indexed peer-reviewed journals.
Research Limitations — Read Honestly
Bronchogen's evidence base is almost entirely preclinical and is dominated by a single research program (Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology). Western independent replication is minimal. No double-blind randomized controlled human trials exist. Mainstream respiratory medicine does not recognize Bronchogen as a therapeutic. The gap between the proposed mechanism (epigenetic bioregulation via direct DNA binding) and what has been rigorously demonstrated (some DNA thermostability shifts, nuclear penetration, and differentiation-marker changes in cell culture) is wide. Treat any community or vendor claim that Bronchogen "treats" asthma or COPD as unsupported.
Human Data
The synthetic tetrapeptide Bronchogen (AEDL) has not been evaluated in published randomized controlled human trials. The accessible human-use information consists of:
- Broncholin historical clinical experience (not AEDL) — The polypeptide parent extract was used observationally in Soviet-era pulmonology. Case-series and single-arm reports described symptomatic improvements in chronic bronchitis and post-infectious respiratory recovery. These reports predate modern randomized-trial methodology, are largely untranslated from Russian, and apply to the crude extract, not the defined AEDL tetrapeptide.
- Khavinson "Revilab" / NPCRiZ post-market observations — The Khavinson bioregulator product line has been marketed in Russia as a dietary supplement since the early 2000s; observational and clinician-reported experience exists but does not meet the evidentiary standard of a controlled human trial.
- Community self-experimentation — Longevity-focused users and Khavinson-protocol practitioners have self-reported using Bronchogen in short-course oral or injectable cycles for "respiratory tissue support" in the context of a broader bioregulator stack. These are anecdotal; selection bias, concurrent-use confounding, and placebo effects dominate.
- No WADA-relevant ergogenic data — There is no published evidence that Bronchogen affects exercise performance, VO₂ max, FEV1 in athletes, or anti-doping-relevant endpoints.
- No pharmacokinetics in humans — No human PK/ADME data for AEDL are published. The general Khavinson assumption — that short peptides are absorbed orally and reach tissues at low nanomolar concentrations — rests on animal studies, not on validated human exposure-response data.
In the context of Western evidence-based medicine, Bronchogen would be described as a preclinical research compound with no established human efficacy for any indication.
Position Within Evidence-Based Respiratory Medicine
Asthma, COPD, bronchiectasis, and allergic airway disease each have mature evidence-based management pathways. Asthma treatment is structured around inhaled corticosteroid + long-acting β2 agonist combinations, leukotriene modifiers, long-acting muscarinic antagonists in more severe disease, and biologics (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab) for type 2 and allergic phenotypes. COPD management centers on smoking cessation, inhaled therapy (LAMA, LAMA+LABA, triple therapy in appropriate patients), pulmonary rehabilitation, oxygen where indicated, and surgical or bronchoscopic intervention in selected cases. Bronchiectasis care involves airway clearance, targeted antimicrobial therapy, and management of exacerbations. Each of these pathways has extensive RCT support and outcome data.
Bronchogen sits outside all of this. It has no respiratory-guideline recognition, no biomarker-validated effect, and no human exacerbation / FEV1 / quality-of-life data. A user with asthma, COPD, or bronchiectasis should continue evidence-based care uninterrupted. Adding a research-grade peptide on top of standard care may be a research-chemical choice, but it is not a respiratory therapeutic in any defensible sense.
Where Bronchogen is most plausibly positioned — and where the Khavinson-program framing is most coherent — is as a course-based "respiratory tissue support" compound in the context of general aging and longevity optimization, alongside other Khavinson peptides. That framing does not make efficacy claims that the evidence cannot support. It also avoids the error of confusing "mucosal tissue bioregulatory effects on cell culture" with "treatment of respiratory disease."
Dosing from the Literature
There is no published clinical-trial-derived human dose for Bronchogen. The doses below summarize the Khavinson bioregulator "protocol framework" and common community practice in the research/longevity space. This is not FDA-approved prescribing.
| Form | Typical Dose | Frequency | Cycle / Notes |
|---|
| Oral capsule (Khavinson BAD — Revilab / NPCRiZ) | 200–400 μg | 1–2× daily | Microdose oral capsule product. 10–20 day course, typically 2–3 courses per year per Khavinson protocol. |
| Oral lyophilized research peptide | 5–10 mg | Once daily | Community-level use of the injectable-grade research peptide administered sublingually/orally. Dose is order(s) of magnitude higher than the Revilab capsule — oral bioavailability of short peptides is poorly characterized. |
| Subcutaneous / IM injection | 100–200 μg | Once daily | Less common; community protocols for injectable administration. 10–20 day courses. |
| Course length | 10–20 days | — | Standard Khavinson bioregulator cycle length. Proposed persistence of gene-expression effects is the rationale for repeated short courses rather than continuous dosing. |
| Cycle frequency | 2–3 courses per year | — | Seasonal timing (e.g., before winter respiratory-infection season) is a common preference in community protocols. |
Dosing Disclaimer
There is a ~50× dosage gap between the Khavinson BAD oral microdose (100s of micrograms) and the research-peptide community oral dose (single-digit milligrams) — without a validated human PK study, it is not possible to say which (if either) corresponds to a biologically active exposure in target tissue. Community dosing should not be treated as clinically validated. Self-administration of imported research-grade peptides is regulated in most jurisdictions. Consult a licensed clinician.
Reconstitution & Storage
Bronchogen as a research peptide is supplied lyophilized in 10 mg or 20 mg vials. The oral Revilab / NPCRiZ product is pre-formulated and does not require reconstitution.
| Vial | BAC Water | Concentration | 100 μg Dose | 200 μg Dose |
|---|
| 10 mg | 2 mL | 5 mg/mL (5,000 μg/mL) | 2 units (0.02 mL) | 4 units (0.04 mL) |
| 10 mg | 5 mL | 2 mg/mL (2,000 μg/mL) | 5 units (0.05 mL) | 10 units (0.10 mL) |
| 20 mg | 2 mL | 10 mg/mL (10,000 μg/mL) | 1 unit (0.01 mL) | 2 units (0.02 mL) |
| 20 mg | 5 mL | 4 mg/mL (4,000 μg/mL) | 2.5 units (0.025 mL) | 5 units (0.05 mL) |
- Reconstitution — Inject bacteriostatic water slowly down the vial wall at a 45° angle. Swirl gently until fully dissolved; do not shake. Solution should be clear and colorless.
- Storage (lyophilized) — Stable at 2–8°C protected from light; can be kept at −20°C for longer-term storage. Avoid repeated freeze-thaw cycles.
- Storage (reconstituted) — Refrigerate at 2–8°C; use within 21–28 days. Do not freeze reconstituted solution. Short peptides without stabilizers can aggregate or degrade.
- Oral-capsule product — Store per manufacturer label, typically room temperature and protected from moisture.
- Inspection — Discard if solution is cloudy, shows precipitate, or has changed color.
→ Use the Kalios Dosing Calculator for exact syringe units
Side Effects & Risks
Important
Bronchogen is a Khavinson short peptide with no human RCTs in English. Safety rests on Russian preclinical work and self-experimenter reports. Bring this to your provider before any course.
- Generally reported well-tolerated — In Russian clinical-experience reports and community self-administration, Bronchogen oral capsules and injectables are typically described as well tolerated, without systematic adverse-event signals.
- Injection-site reactions — Mild erythema, induration, or local discomfort at SubQ/IM injection sites. Typically self-limited.
- Mild GI effects (oral) — Occasional transient nausea or mild GI discomfort reported with oral dosing; not commonly limiting.
- No rigorous toxicology data in humans — Modern ICH-standard GLP toxicology packages (rodent 28-day, 90-day, reproductive, genotoxicity) are not publicly available. Safety profile is inferred from decades of Russian observational use, not from regulatory-grade toxicology.
- Not a bronchodilator — Bronchogen does not provide acute bronchodilation and is not a substitute for inhaled β2 agonists, corticosteroids, leukotriene modifiers, or biologics in asthma or COPD. Using Bronchogen as a replacement for evidence-based respiratory medications is dangerous.
- Allergy / hypersensitivity — Rare hypersensitivity reactions are biologically plausible for any parenteral peptide; clinical signal is low based on available reports.
- Purity / source concerns — Research-peptide suppliers vary substantially in quality. Independent HPLC + mass-spectrometry Certificates of Analysis are the minimum floor. Oral BAD products have been sold globally under variable QA standards.
- Pregnancy / lactation — No human safety data. Avoid.
- Pediatric use — No controlled safety data. Avoid.
- Drug interactions — No clinically relevant interactions documented; pharmacokinetic studies are lacking. Use conservatively alongside other peptides or immunomodulators.
- WADA status — Bronchogen is not specifically named on the 2026 WADA Prohibited List. Short-peptide bioregulators generally are not classified in current S2 categories, but athletes should confirm via sport federation and not assume safe harbor.
- Theoretical epigenetic concerns — A compound that is hypothesized to directly modulate DNA/promoter activity carries theoretical off-target risk. Whether Bronchogen reaches target tissue at concentrations sufficient to act on DNA in humans is unknown.
Bloodwork & Monitoring
- Pulmonary function tests (spirometry) — FEV1, FVC, FEV1/FVC at baseline and after a course — objective respiratory measure, particularly for users with pre-existing chronic respiratory conditions monitored by their primary clinician.
- CBC with differential — Track eosinophils and neutrophils (airway inflammation phenotypes).
- CRP / hs-CRP — Systemic inflammation marker; useful when the user's goal is chronic-inflammation reduction.
- Comprehensive metabolic panel — Baseline liver and renal function; unlikely to be affected by a short peptide but standard for any compound program.
- IgE (if allergic asthma) — Optional baseline if atopic; not expected to shift with Bronchogen but useful as context.
- Oxygen saturation (pulse oximetry) — At rest and on exertion for users with baseline hypoxemia. Not a response marker.
- Subjective symptom diary — Cough frequency, sputum volume, dyspnea (mMRC), exacerbation events — most sensitive clinical readout for a bioregulatory intervention.
- Repeat at 3 months — After two Khavinson-protocol courses; assess whether continued use is warranted.
Commonly Stacked With
Chonluten is the Khavinson bioregulator for gastrointestinal mucosa (EDG). Pairing Chonluten and Bronchogen targets the two largest mucosal compartments (respiratory + GI) within the common-mucosal-immune-system framework. Both are preclinical peptides; co-administration is a community practice, not a clinically validated combination.
Khavinson's thymic bioregulators are often co-cycled with tissue-specific peptides to provide a broader immune-axis foundation. Mechanistically complementary framing: thymic peptides modulate T-cell and innate-immune compartments; Bronchogen targets the bronchial epithelium.
LL-37 — antimicrobial mucosal defense
LL-37 is a cathelicidin antimicrobial peptide with direct antimicrobial activity and broader mucosal-defense effects. A mechanistically distinct companion for respiratory-infection-focused protocols. Clinical evidence for the combination does not exist; mechanistic logic only.
Epithalon (AEDG, pineal/telomerase-axis bioregulator) is the most-studied Khavinson peptide and is commonly included in longevity-oriented bioregulator stacks alongside tissue-specific peptides such as Bronchogen.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
Bronchogen is not approved by the U.S. FDA for any indication and has not been the subject of an IND or NDA filing. It is also not approved by the European Medicines Agency.
In Russia, Khavinson short-peptide bioregulators are marketed primarily as "biologically active additives" (BAD — dietary supplement category) through the St. Petersburg Institute of Bioregulation and Gerontology's commercial affiliates (NPCRiZ, Revilab). Bronchogen itself is sold in this category. It is not a registered pharmaceutical in Russia; the parent extract Broncholin has a separate historical status.
Bronchogen is not on the FDA Category 2 Bulk Drug Substances list, nor is it among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. It is unlikely to achieve a U.S. regulatory pathway absent a sponsor undertaking formal clinical development.
Bronchogen is not specifically named on the WADA Prohibited List. Athletes should consult their sport-specific federation before use.
Cost & Access
Bronchogen is not approved for human use in the United States. The oral BAD form is sold internationally through Khavinson-affiliated distributors; the injectable lyophilized peptide is available through research-chemical suppliers for laboratory research use only. Personal-use import to the U.S. occupies a legal gray zone; bulk import is enforced against.
No U.S. compounding pharmacy can legally compound Bronchogen — it has no FDA-approved reference product and is not on the Category 1 bulk substance list. Purity verification via third-party HPLC and mass-spectrometry COA is the practical quality floor for research-peptide supply, particularly given the origin chain back to a small number of Russian manufacturers.
Bronchogen is not among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. Absent formal FDA development, it will remain unavailable through legitimate U.S. clinical channels.
Access and availability information as of April 2026. Kalios does not sell compounds.
Related Compounds
People researching Bronchogen often also look at these:
Khavinson tripeptide (Glu-Asp-Leu). Hepatic/immune short-peptide bioregulator.
Khavinson tetrapeptide (Lys-Glu-Asp-Trp). Pancreas-oriented bioregulator.
Khavinson tripeptide (Ala-Glu-Asp). Cartilage and joint-oriented short peptide bioregulator.
Khavinson tetrapeptide (Ala-Glu-Asp-Pro). Cerebral cortex-oriented bioregulator.
Key References
- Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide Bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine. 2011;150(3):375-377. DOI: 10.1007/s10517-011-1144-z.
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and the specific interaction of the peptides with deoxyribooligonucleotides and DNA in vitro. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID: 22117548.
- Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148-151. PMID: 22808513.
- Gumen AV, Kozinets IA, Shanin SN, Malinin VV, Rybakina EG. Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides. Bulletin of Experimental Biology and Medicine. 2006;142(3):360-362. PMID: 17266159.
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147. DOI: 10.3390/molecules26227053.
- Khavinson VKh. Peptides and ageing. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144. PMID: 12496732. (Program-level review of the Khavinson short-peptide bioregulator framework.)
- Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger Publishers, Basel, 2005. ISBN 3-8055-7903-3. (Book-length exposition of the Khavinson peptide-bioregulator model.)
- Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Reviews and Reports. 2020;16(1):118-125. PMID: 31813120. DOI: 10.1007/s12015-019-09938-8.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19633997.
- Vanyushin BF, Khavinson VKh. Short Biologically Active Peptides as Epigenetic Modulators of Gene Activity. In: Doerfler W, Casadesús J (eds), Epigenetics — A Different Way of Looking at Genetics. Springer International Publishing, 2016. DOI: 10.1007/978-3-319-27186-6_5.
- Kononenko NV, Fedoreyeva LI. Molecular Mechanisms Involved in Regulating Shoot and Root Development of Nicotiana tabacum by Three Peptides. Plants (Basel). 2022;11(11):1436. PMID: 35684208. (AEDL activity observed across kingdoms — interpreted by the authors as evidence of conserved short-peptide recognition.)
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. PMID: 12937682. (Sibling-peptide methodology reference.)
- Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. 1997;19(9-10):501-505. PMID: 9637343. (Foundational Khavinson-program peptide therapy context.)
- Khavinson VKh, Solov'ev AIu, Zhilinskii DV. Molecular mechanism of the peptide regulation of gene expression: a review. Advances in Gerontology. 2012;25(3):447-456. PMID: 23289233. (Program mechanism review including AEDL-class peptides.)
- Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175-178. PMID: 27259486. (Methodology reference — sibling tissue-specific peptide cell-culture paradigm.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team